A retrospective look at 65 patients at Leicester's HIV service from 2024 to 2026 turned up an unexpected rate of HIV viral rebound among GLP-1 users.
Recap by typeshit. Full story at European AIDS Treatment Group.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Hill notes up to 40% of weight lost on these drugs isn't fat, but argues lean mass on a scan and actual muscle are not the same thing.
A Roomba and a smoke detector join the cast of the 30-second spot, the latest in Noom's Lose for Keeps campaign starring Rebel Wilson as its wellness ambassador.
Loading…